{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001335","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.983340+00:00","generated_at":"2026-05-16T11:11:32.037389+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pacira reports preliminary 2025 revenue of $726.4M; EXPAREL sales record high with 7% volume growth","bullets":["Total revenue $726.4M vs $701.0M in FY2024, up 3.6%.","Q4 EXPAREL net sales $155.8M (record) vs $147.7M in Q4 2024, 7% volume growth.","Full-year EXPAREL net sales $575.1M vs $549.0M (+4.8%); ZILRETTA flat at $116.6M.","Repurchased 2.0M shares for $50.0M in Q4; $150M remains under current authorization.","Preliminary unaudited; full Q4/fiscal 2025 results and guidance expected later in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001335","json":"https://secwatch.observer/filing/0001628280-26-001335.json","markdown":"https://secwatch.observer/filing/0001628280-26-001335.md","text":"https://secwatch.observer/filing/0001628280-26-001335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026001335/0001628280-26-001335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026001335/pcrx-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:11:32.037389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}